Pharmacy First Product Information
Calcichew D3 Forte Chewable Tablet Per tablet: Calcium carbonate 1250 mg(equivalent to 500 mg of elemental calcium)Colecalciferol 400 IU(equivalent to 10 micrograms vitamin D3)Contains sorbitol, 390mg; isomalt, 49.90mg; aspartame, 1mg; sucrose, 1.52mg; and soya bean oil, hydrogenated, 0.30mg. For a full list of excipients, see Section Form: Round, white, uncoated and convex tablets.Therapeutic indications: The treatment and prevention of vitamin D/calcium deficiency (characterised by raised serum alkaline phosphatase levels associated with increased bone loss, raised levels of serum PTH and lowered 25-hydroxyvitamin D) particularly in the housebound and institutionalised elderly subjects.The supplementation of vitamin D and calcium as an adjunct to specific therapy for osteoporosis, in pregnancy, in established vitamin D dependent osteomalacia, and in other situations requiring therapeutic supplementation of malnutrition.Dosage Adults and elderly: 2 chewable tablets per day, preferably one tablet morning and evening.The tablet may be chewed or sucked.Dosage in hepatic impairment:No dose adjustment is required.Dosage in renal impairment:Calcichew-D3 Forte Chewable Tablets should not be used in patients with severe renal impairment.Contraindications Diseases and/or conditions resulting in hypercalcaemia and/or hypercalciuria Nephrolithiasis Hypervitaminosis DHypersensitivity to soya or peanut Hypersensitivity to the active substances or to any of the excipients Special warnings and precautions for use During long-term treatment, serum calcium levels should be followed and renal function should be monitored through measurements of serum creatinine. Monitoring is especially important in elderly patients on concomitant treatment with cardiac glycosides or diuretics (see section 4.5) and in patients with a high tendency to calculus formation. In case of hypercalcaemia or signs of impaired renal function the dose should be reduced or the treatment discontinued.Vitamin D should be used with caution in patients with impairment of renal function and the effect on calcium and phosphate levels should be monitored. The risk of soft tissue calcification should be taken into account. In patients with severe renal insufficiency, vitamin D in the form of colecalciferol is not metabolised normally and other forms of vitamin D should be used (see section 4.3, contraindications).Calcichew-D3 Forte Chewable Tablets should be prescribed with caution to patients suffering from sarcoidosis because of the risk of increased metabolism of vitamin D to its active form. These patients should be monitored with regard to the calcium content in serum and urine.Calcichew-D3 Forte Chewable Tablets should be used with caution in immobilised patients with osteoporosis due to the increased risk of hypercalcaemia.The content of colecalciferol (400 IU) in Calcichew-D3 Forte Chewable Tablets should be considered when prescribing other medicinal products containing vitamin D. Additional doses of calcium or vitamin D should be taken under close medical supervision. In such cases it is necessary to monitor serum calcium levels and urinary calcium excretion frequently.Calcichew D3 Forte Chewable Tablets contain aspartame (a source of phenylalanine) which may be harmful for people with phenylketonuria.Calcichew D3 Forte Chewable Tablets contain sorbitol (E420), isomalt and sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.Calcichew D3 Forte Chewable Tablets are not intended for use in children.Interaction with other medicinal products and other forms of interaction Thiazide diuretics reduce the urinary excretion of calcium. Due to increased risk of hypercalcaemia, serum calcium should be regularly monitored during concomitant use of thiazide diuretics.Systemic corticosteroids reduce calcium absorption. During concomitant use, it may be necessary to increase the dose of Calcichew-D3 Forte Chewable Tablets.Simultaneous treatment with ion exchange resins such as cholestyramine or laxatives such as paraffin oil may reduce the gastrointestinal absorption of vitamin D.Calcium carbonate may interfere with the absorption of concomitantly administered tetracycline preparations. For this reason, tetracycline preparations should be administered at least two hours before, or four to six hours after, oral intake of calcium.Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D. Patients should be monitored with regard to electrocardiogram (ECG) and serum calcium levels.If a bisphosphonate or sodium fluoride is used concomitantly, this preparation should be administered at least three hours before the intake of Calcichew-D3 Forte Chewable Tablets since gastrointestinal absorption may be reduced. Oxalic acid (found in spinach and rhubarb) and phytic acid (found in whole cereals) may inhibit...
Pharmacy First Information
Pharmacy First: Big Brands, Low Prices Pharmacy First is a well trusted and fast growing UK based Online Pharmacy. With a wealth of top quality products and pharmacists on hand to answer any queries, Pharmacy First is a company that you can trust.
Pharmacy First Site Offers
Check out the latest offers available at our website.
Brand :
Shire
Retailer :
Pharmacy First
Category :
Vitamins & Supplements
